<span item_type="fundamental" item_id="ef923d1de7eb41067fd5131ed76a5709" counter_id="ST/US/XFOR" env="prod"></span><span item_type="announcement" item_id="579414527444649473" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 1.765 M, missing the estimate of USD 1.902 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.69, beating the estimate of USD -0.7875.</p><p></p><h3>Segment Revenue</h3><ul><li>Net product sales were $1.6 million for the three months and $4.3 million for the nine months ended September 30, 2025, entirely from XOLREMDI product sales in the United States. In comparison, net product sales were $0.6 million and $1.1 million for the same periods in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm"></span></li><li>License and other revenue was $0.2 million for the three months and $28.3 million for the nine months ended September 30, 2025, attributable to the Company’s Norgine out-licensing agreement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Operating loss was $27.5 million for the three months ended September 30, 2025, compared to $34.5 million for the same period in 2024. For the nine months ended September 30, 2025, operating loss was $63.2 million, compared to $0.7 million in 2024, with the latter period benefiting from a $105.0 million gain on the sale of a priority review voucher.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm"></span></li><li>Net loss for the three months ended September 30, 2025, was $29.8 million, or $0.69 per share, compared to a net loss of $36.7 million, or $5.48 per share, for the same period in 2024. For the nine months ended September 30, 2025, net loss was $55.3 million, or $2.87 per share, compared to net income of $2.4 million, or $0.35 per share, for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash, cash equivalents, and short-term investments totaled $122.2 million as of September 30, 2025. The company completed a public offering on October 27, 2025, with net proceeds of $145.6 million, extending the cash runway to the end of 2028.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company achieved $13 million in annualized cost savings from a 50% workforce reduction as part of its strategic restructuring.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>X4 Pharmaceuticals expects to complete the 4WARD Phase 3 trial, file a potential sNDA for chronic neutropenia, and launch mavorixafor in this new indication by the end of 2028. The company has a strengthened cash position with a runway extending to the end of 2028, supported by recent financings totaling $240.3 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm"></span></li></ul>

X4 Pharmaceuticals | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 1.765 M